Danaher (DHR) is up about 3% as the market revisits its February 17, 2026 agreement to acquire Masimo in an all-cash transaction valued at roughly $9.9 billion (including assumed debt and net of acquired cash). The acquisition is framed as a strategic expansion of Danaher’s Diagnostics platform into patient monitoring, with the target expected to operate as a standalone company within the Diagnostics segment after close. (investors.danaher.com)

Danaher said the Masimo purchase is expected to be accretive to adjusted diluted EPS by about $0.15 to $0.20 in the first full year after completion and roughly $0.70 in the fifth full year, supported by expected synergies. Danaher also highlighted Masimo’s long-term profile as high-single-digit core revenue growth, which would lift the Diagnostics segment’s growth outlook over time. (investors.danaher.com)

The transaction requires Masimo shareholder approval and regulatory clearances, with closing expected in the second half of 2026. Traders are likely watching for incremental milestones tied to the regulatory process and shareholder vote timing, plus any updated commentary from Danaher as it approaches its next earnings catalyst. (finance.yahoo.com)